$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

$ormp Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024020485 Filed on March 06, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue		$0.00	$1.340M
YoY Change		-100.0%	-50.43%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.783M	$2.111M	$8.425M
YoY Change	23.22%	-32.86%	-46.21%
% of Gross Profit
Research & Development	$1.179M	$1.766M	$8.971M
YoY Change	-73.37%	-75.73%	-67.54%
% of Gross Profit
Depreciation & Amortization	$56.00K	$53.00K	$196.0K
YoY Change	51.35%	211.76%	237.93%
% of Gross Profit
Operating Expenses	$1.179M	$3.877M	$8.971M
YoY Change	-73.37%	-62.8%	-67.54%
Operating Profit	-$2.962M		-$15.77M
YoY Change	-43.13%		-61.16%
Interest Expense	$592.0K	$17.17M	$2.037M
YoY Change	-62.93%	1610.46%	-41.35%
% of Operating Profit
Other Income/Expense, Net	$5.088M		$22.89M
YoY Change	218.6%		8571.97%
Pretax Income	$1.534M	$13.30M	$5.088M
YoY Change	-142.48%	-252.2%	-54.42%
Income Tax		$0.00
% Of Pretax Income		0.0%
Net Earnings	$1.536M	$13.34M	$5.525M
YoY Change	-142.54%	-256.1%	-114.63%
Net Earnings / Revenue			412.31%
Basic Earnings Per Share	$0.04		$0.14
Diluted Earnings Per Share	$0.04	$0.32	$0.14
COMMON SHARES
Basic Shares Outstanding	40.52M shares	40.34M shares	40.32M shares
Diluted Shares Outstanding	41.56M shares		40.57M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.94M	$119.6M	$162.0M
YoY Change	-22.59%	193.05%	4.06%
Cash & Equivalents	$18.58M	$9.055M	$9.055M
Short-Term Investments	$367.0K	$110.6M	$153.0M
Other Short-Term Assets	$501.0K	$537.0K	$537.0K
YoY Change	-64.79%	-61.34%	-61.34%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$177.1M	$162.6M	$162.6M
YoY Change	14.14%	3.48%	3.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$819.0K	$873.0K	$1.567M
YoY Change	-16.17%	7.12%	-13.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$25.10M	$56.37M	$56.37M
YoY Change	827.26%	1982.49%	1982.49%
Other Assets	$29.00K	$27.00K	$27.00K
YoY Change	20.83%	12.5%	12.5%
Total Long-Term Assets	$26.56M	$57.97M	$57.97M
YoY Change	474.45%	1178.78%	1178.78%
TOTAL ASSETS
Total Short-Term Assets	$177.1M	$162.6M	$162.6M
Total Long-Term Assets	$26.56M	$57.97M	$57.97M
Total Assets	$203.7M	$220.6M	$220.6M
YoY Change	27.46%	36.44%	36.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.267M	$1.609M	$551.0K
YoY Change	-68.75%	-61.3%	-74.67%
Accrued Expenses	$254.0K	$267.0K	$1.325M
YoY Change	4.96%	8.1%	-40.29%
Deferred Revenue
YoY Change
Short-Term Debt	$32.03M	$51.01M	$51.01M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$33.56M	$53.21M	$53.21M
YoY Change	574.9%	826.11%	826.11%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.375M	$4.444M	$4.444M
YoY Change	-6.12%	-6.24%	-6.24%
Total Long-Term Liabilities	$4.375M	$4.444M	$4.444M
YoY Change	-6.12%	-6.24%	-6.24%
TOTAL LIABILITIES
Total Short-Term Liabilities	$33.56M	$53.21M	$53.21M
Total Long-Term Liabilities	$4.375M	$4.444M	$4.444M
Total Liabilities	$37.93M	$57.66M	$56.73M
YoY Change	293.8%	449.86%	477.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$156.0M	-$157.6M
YoY Change	-6.28%	-3.39%
Common Stock	$322.7M	$321.4M
YoY Change	66980.87%	67416.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$166.6M	$163.8M	$163.8M
YoY Change
Total Liabilities & Shareholders Equity	$203.7M	$220.6M	$220.6M
YoY Change	27.46%	36.44%	36.44%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	$1.536M	$13.34M	$5.525M
YoY Change	-142.54%	-256.1%	-114.63%
Depreciation, Depletion And Amortization	$56.00K	$53.00K	$196.0K
YoY Change	51.35%	211.76%	237.93%
Cash From Operating Activities	-$1.476M	-$1.418M	-$10.30M
YoY Change	-73.4%	-82.41%	-63.12%
INVESTING ACTIVITIES
Capital Expenditures	$2.000K	$3.000K	$254.0K
YoY Change	-98.99%	-99.03%	-48.79%
Acquisitions
YoY Change
Other Investing Activities	$30.00M	$30.00M	-$72.78M
YoY Change	-330.7%	159.34%	-337.03%
Cash From Investing Activities	$30.00M	$30.00M	-$73.04M
YoY Change	-327.21%	166.4%	-341.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$2.428M
YoY Change			-77.13%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$19.00M	-25.00M	$51.98M
YoY Change	-881.89%	-698.8%	382.22%
NET CHANGE
Cash From Operating Activities	-$1.476M	-1.418M	-$10.30M
Cash From Investing Activities	$30.00M	30.00M	-$73.04M
Cash From Financing Activities	-$19.00M	-25.00M	$51.98M
Net Change In Cash	$9.521M	3.579M	-$31.41M
YoY Change	-158.2%	-51.46%	-341.46%
FREE CASH FLOW
Cash From Operating Activities	-$1.476M	-$1.418M	-$10.30M
Capital Expenditures	$2.000K	$3.000K	$254.0K
Free Cash Flow	-$1.478M	-$1.421M	-$10.55M
YoY Change	-74.29%	-83.02%	-62.87%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2022Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent		usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-35813
CY2023	dei	Entity Registrant Name EntityRegistrantName	ORAMED PHARMACEUTICALS INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-0376008
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1185 Avenue of the Americas
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Third Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10036
CY2023	dei	City Area Code CityAreaCode	844
CY2023	dei	Local Phone Number LocalPhoneNumber	967-2633
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.012
CY2023	dei	Trading Symbol TradingSymbol	ORMP
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	130525522	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	40519160	shares
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	dei	Auditor Name AuditorName	Kesselman & Kesselman
CY2023	dei	Auditor Firm AuditorFirmId	1309
CY2023	dei	Auditor Location AuditorLocation	Tel Aviv, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9055000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40464000	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	95279000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	111513000	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	3743000	usd
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	57713000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	537000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1389000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	162584000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	157109000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	7000	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	7000	usd
CY2023Q4	ormp	Investments At Fair Value InvestmentsAtFairValue	51035000	usd
CY2023Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	1807000	usd
CY2023Q4	ormp	Other Nonmarketable Equity Securities Noncurrent OtherNonmarketableEquitySecuritiesNoncurrent	3524000	usd
CY2022Q4	ormp	Other Nonmarketable Equity Securities Noncurrent OtherNonmarketableEquitySecuritiesNoncurrent	2700000	usd
CY2023Q4	ormp	Amounts Funded In Respect Of Employee Rights Upon Retirement AmountsFundedInRespectOfEmployeeRightsUponRetirement	27000	usd
CY2022Q4	ormp	Amounts Funded In Respect Of Employee Rights Upon Retirement AmountsFundedInRespectOfEmployeeRightsUponRetirement	24000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	873000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	815000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	694000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	987000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	57967000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	4533000	usd
CY2023Q4	us-gaap	Assets Assets	220551000	usd
CY2022Q4	us-gaap	Assets Assets	161642000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1609000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	4158000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	51013000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1340000	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	325000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	1000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	267000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	247000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	53214000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5746000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4000000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-36561000	usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-437000	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1203000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	5088000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-37764000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.14
CY2022Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4000000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	28000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	21000	usd
CY2023Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	11000	usd
CY2022Q4	us-gaap	Taxes Payable Current And Noncurrent TaxesPayableCurrentAndNoncurrent	11000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	342000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	647000	usd
CY2023Q4	us-gaap	Other Liabilities OtherLiabilities	63000	usd
CY2022Q4	us-gaap	Other Liabilities OtherLiabilities	61000	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4444000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4740000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.012
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.012
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	60000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40338979	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	40338979	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39563888	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39563888	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	485000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	476000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	320892000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	314417000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-157556000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-163081000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	163821000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	151812000	usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-928000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-656000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	162893000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	151156000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	220551000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	161642000	usd
CY2023	us-gaap	Revenues Revenues	1340000	usd
CY2022	us-gaap	Revenues Revenues	2703000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8971000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27639000	usd
CY2023	ormp	Selling And Marketing Expenses SellingAndMarketingExpenses	-287000	usd
CY2022	ormp	Selling And Marketing Expenses SellingAndMarketingExpenses	1851000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8425000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13811000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-15769000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-40598000	usd
CY2023	us-gaap	Interest Expense InterestExpense	2037000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	22894000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2934000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5088000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37664000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	5088000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-37764000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	5525000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.94
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.14
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.94
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40315068	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38997649	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40566901	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38997649	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	151156000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	9000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2428000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	4047000	usd
CY2023	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	165000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	5088000	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	162893000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	166610000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	22000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11500000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	62000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	11119000	usd
CY2022	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	390000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	783000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-37764000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	151156000	usd
CY2023	us-gaap	Profit Loss ProfitLoss	5088000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-37764000	usd
CY2023	us-gaap	Depreciation Depreciation	196000	usd
CY2022	us-gaap	Depreciation Depreciation	58000	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	13000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	2172000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1550000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-16392000	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	763000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	4212000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	11509000	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	9000	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	22000	usd
CY2023	ormp	Proceeds From Funds In Respect Of Employee Rights Upon Retirement ProceedsFromFundsInRespectOfEmployeeRightsUponRetirement	3000	usd
CY2023	ormp	Accrued Interest On Shortterm Borrowings To Maturity AccruedInterestOnShorttermBorrowingsToMaturity	1463000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-852000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-268000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-2225000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-376000	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	8000	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-93000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1340000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-703000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	7000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1000	usd
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	2000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-38000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10295000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27918000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	254000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	496000	usd
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	24000	usd
CY2023	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	91369000	usd
CY2022	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	151700000	usd
CY2022	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	5000	usd
CY2023	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	99550000	usd
CY2022	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	2700000	usd
CY2023	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	5000000	usd
CY2023	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	109760000	usd
CY2022	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	178200000	usd
CY2023	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	3375000	usd
CY2022	us-gaap	Proceeds From Sale Of Held To Maturity Securities ProceedsFromSaleOfHeldToMaturitySecurities	6886000	usd
CY2022	ormp	Funds In Respect Of Employee Rights Upon Retirement Investing Activities FundsInRespectOfEmployeeRightsUponRetirementInvestingActivities	-2000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-73038000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	30211000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2428000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11500000	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	62000	usd
CY2023	us-gaap	Proceeds From Construction Loans Payable ProceedsFromConstructionLoansPayable	99550000	usd
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	50000000	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	783000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51978000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10779000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-54000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-64000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-31409000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13008000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40464000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	27456000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9055000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40464000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	100000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	574000	usd
CY2023	us-gaap	Notes Issued1 NotesIssued1	5156000	usd
CY2022	us-gaap	Notes Issued1 NotesIssued1	1844000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	730000	usd
CY2021Q1	ormp	Capital Stock Shares Issued CapitalStockSharesIssued	1890000	shares
CY2021Q1	ormp	Shares Issued And Outstanding Percentage SharesIssuedAndOutstandingPercentage	0.63	pure
CY2023Q1	ormp	Exhibited Over Percentage ExhibitedOverPercentage	0.01	pure
CY2023Q3	ormp	Purchase Price PurchasePrice	105000000	usd
CY2023Q3	ormp	Non Refundable Closing Fee NonRefundableClosingFee	450000	usd
CY2023Q3	ormp	Additional Cash Paid AdditionalCashPaid	5000000	usd
CY2023Q3	ormp	Debt Conversions Period DebtConversionsPeriod	P18M
CY2023Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	101875000	usd
CY2023Q3	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	875000	usd
CY2023Q3	us-gaap	Loan Processing Fee LoanProcessingFee	1000000	usd
CY2023Q3	ormp	Aggregate Face Amount AggregateFaceAmount	99550000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.5in"><b>c.</b></td> <td style="text-align: justify"><b>Use of estimates in the preparation of financial statements</b></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock-based compensation and to the investments at fair value (for further details, see note 4).</p>
CY2023Q4	us-gaap	Marketable Securities MarketableSecurities	110555000	usd
CY2022Q4	us-gaap	Marketable Securities MarketableSecurities	437000	usd
CY2023	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	20382000	usd
CY2023	us-gaap	Deferred Income Revenue Recognized DeferredIncomeRevenueRecognized	1340000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	2000000	usd
CY2023	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	2000000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in; text-align: justify"> </td> <td style="width: 0.5in; text-align: justify"><b>k.</b></td> <td style="text-align: justify"><b>Concentration of credit risks</b></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents, short and long-term deposits, which are deposited in major financial institutions, marketable securities, and the Note (as defined herein). The Company is of the opinion that the credit risk in respect of these balances is remote, except for the Note (as defined herein) for which the credit risk is reflected in its fair value measurement (for further details, see note 4).</p>
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.50	pure
CY2023	ormp	Liability Is Expected LiabilityIsExpected	P12Y
CY2023	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.5in"><b>m.</b></td> <td style="text-align: justify"><b>Revenue recognition</b></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><i>HTIT</i></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in">On November 30, 2015, the Company entered into a Technology License Agreement, with Hefei Tianhui Incubator of Technologies Co. Ltd. (“HTIT”) and on December 21, 2015, the parties entered into an Amended and Restated Technology License Agreement that was further amended by the parties on June 3, 2016 and July 24, 2016 (the “HTIT License Agreement”).</p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in">As of December 31, 2023, an aggregate amount of $22,382 was allocated to the HTIT License Agreement, all of which were received through the balance sheet date. Through December 31, 2023, the Company recognized revenue associated with this agreement in the aggregate amount of $20,382, of which $1,340 was recognized in the twelve month period ended December 31, 2023, and deferred the remaining amount of $2,000, which is presented as long-term deferred revenues on the consolidated balance sheet.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><i>Medicox</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On November 13, 2022, the Company entered into a distribution license agreement (“Medicox License Agreement”) with Medicox Co., Ltd. (“Medicox”). The Medicox License Agreement grants Medicox an exclusive license to apply for regulatory approval and distribute ORMD-0801 in the Republic of Korea. For further details, see note 8c.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under ASC 606 “Revenue from Contracts with Customers,” the Company identified Medicox as a customer and the Medicox License Agreement as a contract with a customer.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company identified a performance obligation in the Medicox License Agreement to stand-ready and provide Medicox with support in its commercialization efforts in the Republic of Korea. This performance obligation includes a non-distinct distribution license for ORMD-0801, which the Company views a predominant item in the combined performance obligation. The Company concluded that the license is not distinct, as no party other than the Company is capable of providing related services to Medicox, and both the license and related services are necessary for the customer to obtain a regulatory approval in the Republic of Korea. In addition, the agreement covers the terms of future manufacturing services, that are contingent on the completion and success of the commercialization efforts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Medicox License Agreement contains a fixed consideration of $2,000, which was received by the Company during the year ended December 31, 2022 and is currently presented under long-term deferred revenues. It also contains variable consideration of contractual milestone payments and sales-based royalties.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company’s obligation to stand-ready and support Medicox will be recognized on a straight-line basis over the period the Company expects to provide support to Medicox. As of December 31, 2023, this support has not commenced, and no revenue was recognized from the Medicox License Agreement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">If Medicox proceeds with the regulatory approval process in the Republic of Korea, the Company expects most of the revenue to be recognized at a later stage, going forward. The Company notes that its Phase 3 trial did not meet its primary or secondary endpoints (see note 1a.1). If Medicox chooses to terminate the agreement as a result of the outcome of the Phase 3 trials, the Company will accelerate revenue recognition and recognize it at such time. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2023	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1227506	shares
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	3356203	shares
CY2023Q4	us-gaap	Lessor Operating Lease Term Of Contract LessorOperatingLeaseTermOfContract	P5Y
CY2023Q4	us-gaap	Deposit Assets DepositAssets	95279000	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	111513000	usd
CY2023Q4	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	595000	usd
CY2022Q4	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	595000	usd
CY2023Q4	us-gaap	Other Investments OtherInvestments	1000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	3306000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-82000	usd
CY2022Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	3224000	usd
CY2023Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	5000000	usd
CY2023	us-gaap	Business Exit Costs1 BusinessExitCosts1	3056000	usd
CY2023	us-gaap	Principal Transactions Revenue PrincipalTransactionsRevenue	5000000	usd
CY2023	us-gaap	Sale Of Stock Percentage Of Ownership After Transaction SaleOfStockPercentageOfOwnershipAfterTransaction	0.099	pure
CY2023	ormp	Warrant Expire WarrantExpire	2027-11-10
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0315	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0315	pure
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	267000	usd
CY2023Q4	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	101875000	usd
CY2023Q4	us-gaap	Other Short Term Investments OtherShortTermInvestments	57713000	usd
CY2023Q4	us-gaap	Other Long Term Investments OtherLongTermInvestments	35353000	usd
CY2023Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	7801000	usd
CY2022Q3	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.05	pure
CY2023	us-gaap	Dividend Income Equity Securities Operating DividendIncomeEquitySecuritiesOperating	824000	usd
CY2023Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	551000	usd
CY2022Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	2175000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	453000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	529000	usd
CY2022Q4	ormp	Accounts Payable To Institutions AccountsPayableToInstitutions	11000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	605000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	1443000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	1609000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current And Noncurrent AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent	4158000	usd
CY2023Q3	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	99550	usd
CY2023	us-gaap	Repayments Of Bank Debt RepaymentsOfBankDebt	50000	usd
CY2023Q4	ormp	Short Term Debt Maturities Repayments Of Principal In Next Twelve Months ShortTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	49550000	usd
CY2023Q4	us-gaap	Other Short Term Borrowings OtherShortTermBorrowings	49550000	usd
CY2023	ormp	Description Of License Agreement DescriptionOfLicenseAgreement	According to the HTIT License Agreement, the Company granted HTIT an exclusive commercialization license in the territory of the People’s Republic of China, Macau and Hong Kong (the “Territory”), related to the Company’s oral insulin capsule, ORMD-0801 (the “Product”). Pursuant to the HTIT License Agreement, HTIT will conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to the Subsidiary’s technology and ORMD-0801 capsule, and will pay to the Subsidiary (i) royalties of 10% on net sales of the related commercialized products to be sold by HTIT in the Territory (“Royalties”), and (ii) an aggregate of $37,500, of which $3,000 was payable immediately, $8,000 will be paid subject to the Company entering into certain agreements with certain third parties, and $26,500 will be paid upon achievement of certain milestones and conditions. In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expiration of the Company’s patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances, to 5%.
CY2023	ormp	Milestone Payment MilestonePayment	20500000	usd
CY2016Q1	ormp	Initial Payment InitialPayment	3000000	usd
CY2020Q3	us-gaap	Purchase Obligation PurchaseObligation	6000000	usd
CY2020Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2000000	usd
CY2023Q4	us-gaap	Receivable With Imputed Interest Face Amount ReceivableWithImputedInterestFaceAmount	2559000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	59000	usd
CY2023	us-gaap	Payments For Fees PaymentsForFees	435	ils
CY2023	us-gaap	Payments For Fees PaymentsForFees	120	usd
CY2022Q1	us-gaap	Area Of Land AreaOfLand	264	sqm
CY2021Q1	us-gaap	Payments For Fees PaymentsForFees	435	ils
CY2021Q1	us-gaap	Payments For Fees PaymentsForFees	120	usd
CY2023	us-gaap	Other Expenses OtherExpenses	236000	usd
CY2022	us-gaap	Other Expenses OtherExpenses	264000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	694000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	987000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	267000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	247000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	342000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	647000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	609000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	894000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y6M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y4M28D
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	214000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	282000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	222000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	120000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	634000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	609000	usd
CY2023	us-gaap	Legal Fees LegalFees	850000	usd
CY2022Q3	ormp	Aggregate Purchase Prices AggregatePurchasePrices	2700000	usd
CY2022Q3	ormp	Percentage Of Stock Issued PercentageOfStockIssued	0.05	pure
CY2022Q3	ormp	Percentage Of Stock Outstanding PercentageOfStockOutstanding	0.05	pure
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	4.13
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	150705	shares
CY2022Q4	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	4.71
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	158375	shares
CY2021Q4	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	4.78
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	4200	shares
CY2022	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice	4.8
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	130705	shares
CY2023	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice	4.8
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	3470	shares
CY2022	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expired In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageExercisePrice	7.81
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	20000	shares
CY2023Q4	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	4.13
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	150705	shares
CY2022Q4	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice	4.71
CY2023Q4	ormp	Sharebased Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number SharebasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	20000	shares
CY2023Q4	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Exercisable In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisableInPeriodWeightedAverageExercisePrice	4.13
CY2022Q4	ormp	Sharebased Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number SharebasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	150705	shares
CY2022Q4	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Exercisable In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisableInPeriodWeightedAverageExercisePrice	4.71
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	150000	shares
CY2022Q1	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	2084000	usd
CY2022Q1	us-gaap	Shares Issued SharesIssued	18000	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.03
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	82875	shares
CY2022Q1	ormp	Expired Terms ExpiredTerms	2032-01-03
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4500	shares
CY2023	ormp	Revaluation Of Securities Net RevaluationOfSecuritiesNet	69000	usd
CY2022	ormp	Revaluation Of Securities Net RevaluationOfSecuritiesNet	763000	usd
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.03
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	7500	shares
CY2022Q2	ormp	Expired Terms ExpiredTerms	2032-05-02
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	34000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	8.47
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights	The options will vest in four annual installments as follows: the first installment vested immediately on the grant date and the remaining three installments shall vest on each of December 31, 2022, 2023 and 2024.
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	665000	usd
CY2023Q2	ormp	Share Based Compensation Arrangement By Share Based Payment Aggregate Shares ShareBasedCompensationArrangementByShareBasedPaymentAggregateShares	245500	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	550000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	20000	shares
CY2023Q2	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	49000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	2.45
CY2023Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	132000	shares
CY2023	us-gaap	Stock Issued During Period Shares Restricted Stock Award Forfeited StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited	110917	shares
CY2023	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	663000	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1479426	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1261426	shares
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	707000	usd
CY2023	ormp	Weighted Average Period WeightedAveragePeriod	P0Y9M18D
CY2023	ormp	Share Based Payment Arrangemen Unrecognized Compensation Costs ShareBasedPaymentArrangemenUnrecognizedCompensationCosts	2693	usd
CY2023	ormp	Share Based Payment Arrangement Compensation Expenses ShareBasedPaymentArrangementCompensationExpenses	26000	usd
CY2022	ormp	Share Based Payment Arrangement Compensation Expenses ShareBasedPaymentArrangementCompensationExpenses	92000	usd
CY2023	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	8016000	usd
CY2022	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	3473000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	176000	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	10000	usd
CY2022	us-gaap	Interest Income Other InterestIncomeOther	100000	usd
CY2023	ormp	Revaluation Of Securities RevaluationOfSecurities	16461000	usd
CY2023	us-gaap	Other Income OtherIncome	143000	usd
CY2022	us-gaap	Other Income OtherIncome	5000	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	24630000	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	3754000	usd
CY2023	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	124000	usd
CY2023	us-gaap	Noninterest Expense Commission Expense NoninterestExpenseCommissionExpense	29000	usd
CY2022	us-gaap	Noninterest Expense Commission Expense NoninterestExpenseCommissionExpense	14000	usd
CY2022	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss	43000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-533000	usd
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	2838000	usd
CY2022	us-gaap	Income Tax Rate Reconciliation Deductions Employee Stock Ownership Plan Dividends IncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends	100000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2022	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2023	ormp	Fees Regarding Scilex Transaction FeesRegardingScilexTransaction	1514000	usd
CY2023	us-gaap	Other Noninterest Expense OtherNoninterestExpense	2037000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-4332000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7290000	usd
CY2023	us-gaap	Income Tax Reconciliation Deductions IncomeTaxReconciliationDeductions	731000	usd
CY2022	us-gaap	Income Tax Reconciliation Deductions IncomeTaxReconciliationDeductions	1152000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-305000	usd
CY2023	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	3773000	usd
CY2022	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	820000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.80	pure
CY2023	ormp	Corporate Taxation Term CorporateTaxationTerm	P20Y
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27757000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27610000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2731000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	5195000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	2611000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	596000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28473000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	32805000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	11604000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-11164000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-6516000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-26500000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5088000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37664000	usd
CY2022	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations	-100000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	5088000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-37664000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	ormp	Statutory Taxbenefit Expense StatutoryTaxbenefitExpense	1068000	usd
CY2022	ormp	Statutory Taxbenefit Expense StatutoryTaxbenefitExpense	-7909000	usd
CY2023	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum		pure
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	11000	usd
CY2022Q4	us-gaap	Tax Credit Carryforward Valuation Allowance TaxCreditCarryforwardValuationAllowance	32805000	usd
CY2023	ormp	Operating Loss Carryforwards Valuation Allowance Additions OperatingLossCarryforwardsValuationAllowanceAdditions	4332000	usd
CY2023Q4	us-gaap	Tax Credit Carryforward Valuation Allowance TaxCreditCarryforwardValuationAllowance	28473000	usd
CY2021Q4	us-gaap	Tax Credit Carryforward Valuation Allowance TaxCreditCarryforwardValuationAllowance	26659000	usd
CY2022	ormp	Operating Loss Carryforwards Valuation Allowance Additions OperatingLossCarryforwardsValuationAllowanceAdditions	-6146000	usd
CY2022Q4	us-gaap	Tax Credit Carryforward Valuation Allowance TaxCreditCarryforwardValuationAllowance	32805000	usd
CY2008Q3	us-gaap	Professional Fees ProfessionalFees	40	usd
CY2022Q4	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	331000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments		usd
CY2022Q4	ormp	Investments At Fair Value InvestmentsAtFairValue		usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Interest Expense InterestExpense		usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022	ormp	Proceeds From Funds In Respect Of Employee Rights Upon Retirement ProceedsFromFundsInRespectOfEmployeeRightsUponRetirement		usd
CY2022	ormp	Accrued Interest On Shortterm Borrowings To Maturity AccruedInterestOnShorttermBorrowingsToMaturity		usd
CY2023	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
CY2023	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments		usd
CY2022	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments		usd
CY2023	ormp	Funds In Respect Of Employee Rights Upon Retirement Investing Activities FundsInRespectOfEmployeeRightsUponRetirementInvestingActivities		usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Proceeds From Construction Loans Payable ProceedsFromConstructionLoansPayable		usd
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation		usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023Q4	ormp	Accounts Payable To Institutions AccountsPayableToInstitutions		usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2023	ormp	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate		pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2023	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax		usd
CY2022	ormp	Revaluation Of Securities RevaluationOfSecurities		usd
CY2022	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax		usd
CY2023	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss		usd
CY2022	ormp	Fees Regarding Scilex Transaction FeesRegardingScilexTransaction		usd
CY2022	us-gaap	Other Noninterest Expense OtherNoninterestExpense		usd
CY2022Q4	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments		usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2023	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2022	us-gaap	Federal Income Tax Expense Benefit Continuing Operations FederalIncomeTaxExpenseBenefitContinuingOperations		usd
CY2023	us-gaap	Foreign Income Tax Expense Benefit Continuing Operations ForeignIncomeTaxExpenseBenefitContinuingOperations		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes		usd
CY2023	us-gaap	Income Tax Rate Reconciliation Deductions Employee Stock Ownership Plan Dividends IncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends		usd
CY2023	ormp	Effective Income Tax Uncertain Tax Position EffectiveIncomeTaxUncertainTaxPosition		usd
CY2022	ormp	Effective Income Tax Uncertain Tax Position EffectiveIncomeTaxUncertainTaxPosition		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease		usd
CY2022	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease		usd
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001176309

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
ormp-20231231_pre.xml	Edgar Link	unprocessable
0001213900-24-020485-index-headers.html	Edgar Link	pending
0001213900-24-020485-index.html	Edgar Link	pending
0001213900-24-020485.txt	Edgar Link	pending
0001213900-24-020485-xbrl.zip	Edgar Link	pending
ea0200896-10k_oramedph.htm	Edgar Link	pending
ea0200896ex10-15_oramed.htm	Edgar Link	pending
ea0200896ex10-16_oramed.htm	Edgar Link	pending
ea0200896ex10-20_oramed.htm	Edgar Link	pending
ea0200896ex10-21_oramed.htm	Edgar Link	pending
ea0200896ex10-22_oramed.htm	Edgar Link	pending
ea0200896ex10-2_oramed.htm	Edgar Link	pending
ea0200896ex10-3_oramed.htm	Edgar Link	pending
ea0200896ex10-5_oramed.htm	Edgar Link	pending
ea0200896ex10-6_oramed.htm	Edgar Link	pending
ea0200896ex23-1_oramed.htm	Edgar Link	pending
ea0200896ex31-1_oramed.htm	Edgar Link	pending
ea0200896ex31-2_oramed.htm	Edgar Link	pending
ea0200896ex32-1_oramed.htm	Edgar Link	pending
ea0200896ex32-2_oramed.htm	Edgar Link	pending
ea0200896ex97-1_oramed.htm	Edgar Link	pending
ex97-1_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ormp-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
ormp-20231231_cal.xml	Edgar Link	unprocessable
ormp-20231231_def.xml	Edgar Link	unprocessable
ormp-20231231_lab.xml	Edgar Link	unprocessable
ea0200896-10k_oramedph_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp

2024 Q1 Form 10-K Financial Statement

#000121390024020485 Filed on March 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP ORAMED PHARMACEUTICALS INC. Stock $ormp

2024 Q1 Form 10-K Financial Statement

#000121390024020485 Filed on March 06, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ORMP
ORAMED PHARMACEUTICALS INC. Stock $ormp